Irbecor H

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Diuretic

Treatment option: Hypertension

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Irbecor H

Quick Facts

Property	Description
Active Ingredients	Irbesartan and Hydrochlorothiazide (HCTZ)
Form	Tablet (Oral Dosage Form)
Pharmacological Class	Angiotensin II Inhibitor with a Thiazide Diuretic
Common Purpose	Management of Hypertension (High Blood Pressure)
Type	Synthetic Fixed-Dose Combination (FDC)

What is Irbecor H and What Type of Medicine is It?

Irbecor H is fundamentally a prescription-only drug classified as an antihypertensive agent, which is a combination medicine specifically used to manage and control Hypertension (high blood pressure). It is designated pharmacologically as an Angiotensin II Inhibitor with a Thiazide Diuretic, a classification that confirms the inclusion of two distinct active entities. The use of two different mechanisms of action is clinically recognized for achieving a better overall blood pressure response compared to increasing the dose of a single agent.

This medication’s essential purpose is to lower elevated arterial pressure, which reduces the workload on the heart and the vascular system. The combination of Irbesartan and Hydrochlorothiazide is an established treatment for those whose blood pressure is not adequately controlled by monotherapy. Other common trade names with this identical Irbesartan/Hydrochlorothiazide formulation include Avalide and Coaprovel, distinguishing Irbecor H as one of several commercial names offering this medically confirmed combination.

The Composition and Form of Irbecor H

The active core of Irbecor H consists of two distinct, synthetic chemical entities: Irbesartan and Hydrochlorothiazide (HCTZ). Irbesartan functions as an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide is a volume-managing Thiazide Diuretic. The medicine is formulated as a fixed-dose combination (FDC) delivered in an oral tablet for ingestion. This structure ensures both the ARB component, which promotes vasodilatation, and the diuretic component, which reduces fluid volume, are taken simultaneously. The FDC design itself represents a key differentiating feature, streamlining complex antihypertensive therapy into a single, straightforward unit.

What side effects are possible with Irbecor H?

Irbecor H, a combination of irbesartan and hydrochlorothiazide, is generally well-tolerated, but like all medications, it can cause side effects. Understanding these potential effects is an important part of patient safety.

Common Side Effects

The most frequently reported side effects are usually mild and may lessen as your body adjusts to the medication. These can include:

Dizziness or lightheadedness, particularly when standing up quickly (orthostatic effects).
Headache
Fatigue or unusual tiredness
Nausea, vomiting, diarrhea, or heartburn
Muscle or joint pain

Serious Side Effects and Warnings

Contact your healthcare provider immediately if you experience any of the following serious symptoms:

Angioedema: Swelling of the face, lips, tongue, or throat, which can cause difficulty breathing or swallowing. This is a rare, severe allergic reaction.
Kidney Problems: Signs such as a significant change in the amount of urine or swelling in the feet or ankles.
Electrolyte Imbalance: Symptoms of high potassium (hyperkalemia) include irregular heartbeat, muscle weakness, or confusion. Symptoms of low sodium (hyponatremia) or other electrolyte issues can involve severe dizziness, muscle cramps, or extreme thirst.
Vision Changes: Sudden decrease in vision or eye pain, which may indicate a serious eye condition like acute angle-closure glaucoma.

Important Safety Information

Pregnancy: Irbecor H must not be used during the second and third trimesters of pregnancy as it can cause serious injury or death to the developing fetus. Stop taking the medicine and contact your doctor immediately if pregnancy is detected.
Sun Exposure: The hydrochlorothiazide component can increase skin sensitivity to the sun, potentially increasing the risk of sunburn and, rarely, non-melanoma skin cancer with long-term use. Use sunscreen and wear protective clothing outdoors.
Monitoring: Regular monitoring of your blood pressure and kidney function, including electrolyte levels (like potassium), is often necessary during treatment.

Overdose and Emergency Response

The official regulatory documentation for Irbecor H (Irbesartan/Hydrochlorothiazide) describes that specific information regarding the treatment of an overdosage with the combination product is not available. Overdose manifestations are defined by the known effects of the individual components. The most likely clinical presentations involve significant Hypotension (excessively low blood pressure) and potential changes in heart rate, such as Tachycardia or **Bradycardia).

The hydrochlorothiazide component contributes to signs of excessive diuresis, leading to dehydration and critical electrolyte depletion, including Hypokalemia, Hyponatremia, and Hypochloremia. A severe outcome noted in the official labeling is the potential for accentuated cardiac arrhythmias, particularly if hypokalemia develops in a patient concurrently receiving digitalis.

For the management of a suspected drug overdose, regulatory authorities mandate that the patient contact a regional Poison Control Centre immediately. Treatment procedures are symptomatic and supportive, requiring close monitoring and specific intervention with fluid and electrolyte replacement. It is officially stated that Irbesartan is not removed by hemodialysis, and the extent of hydrochlorothiazide removal by this method has not been established.

Therapeutic Uses of Irbecor H

What Irbecor H Treats: Main Uses and Benefits

The primary role of Irbecor H is the management of Essential Hypertension (high blood pressure) in adult patients. This combination medicine is commonly used when pressure is not adequately controlled on monotherapy or may be applied as initial therapy for those likely to require multiple agents.

Therapeutic Focus and Benefits

Irbecor H is used for managing conditions characterized by symptoms related to heightened physiological activity, addressing the need for comprehensive blood pressure management in scenarios of chronic, uncontrolled hypertension. The medication is relevant for easing symptoms linked to organ-specific functional stress, particularly in patients with Type 2 Diabetes Mellitus, contributing to the management of associated cardiovascular and systemic risk. Its core use focuses on three key therapeutic domains: sustained arterial pressure management, long-term cardiovascular risk reduction, and support for kidney function in diabetic patients. This combination of uses helps to support the patient during difficult episodes by easing the systemic strain on the cardiovascular system and supports the patient in managing vascular stability over time.

“This application may assist with managing organ-specific functional stress, which is relevant for easing symptoms linked to organ-specific functional stress related to kidney function.”

QuickFact Block

Quick Fact: Relief for Uncontrolled Blood Pressure
Conditions Used For	Essential Hypertension, uncontrolled by single-agent therapy, or as initial therapy in severe cases.
Primary Benefit	Plays a role in managing sustained, elevated arterial pressure and supports the maintenance of vascular stability.
Relevant Patient Group	Adult patients, including those with Type 2 Diabetes Mellitus requiring focused kidney support.

Regulatory References

DailyMed NIH label for Irbesartan and Hydrochlorothiazide

Eligibility and Restrictions for Use

Eligibility and Contraindications for Irbecor H

Irbecor H (irbesartan/hydrochlorothiazide) is a combination medicine used for high blood pressure, but its use is restricted in specific patient populations according to regulatory guidelines.

Do not take Irbecor H if you have:

Contraindicated Populations	Restriction Context
Pregnancy (second and third trimesters)	Fetal injury and death risk. Use in early pregnancy is not recommended.
Anuria (inability to produce urine)	Related to the hydrochlorothiazide component.
Hypersensitivity	Allergy to irbesartan, sulfonamide-derived drugs (like thiazides), or any other component.
Diabetes or Moderate-to-Severe Renal Impairment	Concomitant use with aliskiren-containing medicines is prohibited.
Severe Renal Impairment	Creatinine clearance leq 30 mL/min. Use is not recommended.

Restrictions and Special Considerations:

Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years of age.
Impaired Hepatic Function: Use is not recommended in patients with severe liver problems. For less severe impairment, use with caution, as fluid shifts may be serious.
Primary Aldosteronism: Use is not recommended as patients typically do not respond to this type of medicine.
Volume/Salt Depletion: The medicine should not be used as initial therapy in patients who are dehydrated or have a salt deficiency; this must be corrected before starting treatment.
Lactation: Use is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Irbecor H, a fixed-dose combination of Irbesartan and Hydrochlorothiazide, has officially documented interaction patterns primarily concerning effects on electrolytes, kidney function, and drug exposure.

Documented Interaction Patterns

Classification	Interacting Agents or Condition
Formal Contraindication	Co-administration with Aliskiren is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment.
Exposure/Clearance	Co-administration with Lithium significantly increases its serum concentration due to reduced renal clearance, raising the risk of toxicity.
Pharmacodynamic Effects	Potassium-sparing diuretics, Potassium Supplements, and Potassium-Containing Salt Substitutes may result in hyperkalemia.
Absorption Restriction	Cholestyramine or Colestipol Resins reduce the absorption of the Hydrochlorothiazide component.

Required Constraints and Considerations

Interactions with Non-Steroidal Anti-Inflammatory Agents (NSAIDs) can attenuate the antihypertensive effect and may cause a deterioration of renal function, particularly in elderly or volume-depleted patients. Alcohol consumption is documented to cause a potentiation of orthostatic hypotension. To prevent reduced absorption of the diuretic component, Irbecor H must be administered at least one hour before or four hours after Cholestyramine or Colestipol Resins. The thiazide component may also impair glucose tolerance, which could necessitate a management adjustment for antidiabetic drugs.

Mechanism of Action

Irbecor H is a fixed-dose combination product containing irbesartan and hydrochlorothiazide, which modulate distinct physiological pathways. Irbesartan functions as a selective, insurmountable antagonist of the Angiotensin II Type 1 (AT1) receptor. It binds to the AT1 receptor in tissues such as vascular smooth muscle and the adrenal gland, preventing the binding of the endogenous agonist Angiotensin II. This blockade inhibits Angiotensin II-mediated intracellular signaling cascades, which normally include activation of phospholipase C and increased intracellular calcium. The resulting downstream consequences include the prevention of vasoconstriction and the inhibition of aldosterone secretion from the adrenal cortex. Hydrochlorothiazide, a thiazide diuretic, acts within the renal distal convoluted tubule. Its molecular target is the apical sodium chloride cotransporter (NCC), which it inhibits. This inhibition reduces the reabsorption of sodium and chloride ions from the tubular lumen, leading to increased delivery of these solutes and water to the collecting duct. The system-level physiological consequence of both components is a reduction in total peripheral vascular resistance and plasma volume, resulting in a modulation of systemic arterial pressure.

Dosage and Administration Information

Irbecor H (irbesartan/hydrochlorothiazide) is an oral tablet medicine prescribed as a fixed-dose combination. Proper use is essential for the correct administration of the drug.

Official Administration Guidelines

Administration Scope	Official Instruction
Route of Administration	Oral (taken by mouth).
Dosing Schedule	One tablet once daily. Doses higher than 300 mg/25 mg once daily are not recommended.
Timing in Relation to Meals	May be administered with or without food.
Age Group Rules	Intended for use in adult patients only. Not recommended for children and adolescents.
Renal Impairment	The usual regimen may be followed if creatinine clearance is ge 30 mL/min. Not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min).

Missed Dose Instructions

If a dose is missed, patients should take it as soon as they remember. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular dosing schedule should be continued. Patients are strictly instructed not to double the dose to make up for a missed tablet.

Procedural Summary

The established protocol requires taking one whole tablet once a day. This administration method establishes a consistent daily routine that is not dependent on mealtimes. The dose strength is determined by the prescribing healthcare professional, typically starting with a lower strength (e.g., 150 mg/12.5 mg) and titrating up to a maximum of 300 mg/25 mg once daily, as necessary, after one to two weeks of therapy.

Recent Clinical Evidence

This section describes the findings from clinical research and studies involving the drug Irbecor H (irbesartan/hydrochlorothiazide) combination therapy. These summaries are based on the data collected in the research environment and are not clinical recommendations.

Combination Therapy Studies

Research evaluated whether combination therapy with irbesartan and hydrochlorothiazide was used in participants with high blood pressure (hypertension). Studies compared this approach to monotherapy (using a single drug).

Research Focus	Study Activity
Symptom Collection	Data on the severity of blood pressure changes and the time to initial change were collected.
Quality of Life	One study examined whether the treatment was used in participants where changes in the quality of life were also noted.
Combination with PT	Studies have also investigated the use of the drug in combination with lifestyle interventions, such as physical therapy.

Pharmacokinetics and Data Collection

Studies were conducted to understand the body's processing of the drug components (pharmacokinetics) and to collect information on side effects. This research details how the drug is absorbed, metabolized, and eliminated.

Delivery Method: The new delivery method was a focus of study to track absorption characteristics.
Data Reported: Studies collected pharmacokinetic and safety data, including information on potential side effects in diverse populations.
Liver Function: Monitoring of liver function was part of the data collection in the study protocol.
Subgroup Analysis: One study reported that individuals with mild symptoms experienced potential side effects differently than those with severe symptoms.

Key Limitations

Evidence remains limited on the long-term effects of this combination beyond the typical 5-year study period of certain trials. Research is planned to study long-term safety profiles and effects in specific patient populations, such as pediatrics, where safety and efficacy are not yet fully established.

Key Studies & References

Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender

Frequently Asked Questions (FAQ)

Common questions about Irbecor H (FAQ)

Q: How is Irbecor H different from Irbecor (the medicine without the H)?

A: Irbecor H is a fixed-dose combination product containing two active ingredients. According to official documents, it combines Irbesartan with a diuretic medicine called Hydrochlorothiazide (HCTZ). The medicine named Irbecor, without the 'H', contains only Irbesartan (an angiotensin II receptor blocker).

Q: What conditions besides high blood pressure is Irbecor H approved to treat?

A: Official regulatory documents state that Irbecor H is approved only for the treatment of hypertension, which is high blood pressure. This fixed-dose combination medicine is not approved for any other conditions. The purpose is described as helping to lower elevated arterial pressure.

Q: Does Irbecor H cause weight gain or fluid changes?

A: The hydrochlorothiazide component is described as a diuretic, which works to reduce fluid volume. Official safety documents list fluid-related side effects such as edema (swelling) and risks associated with excessive volume depletion. However, weight gain is not explicitly listed among the commonly reported side effects.

Q: Is a persistent cough a known side effect of Irbecor H?

A: Official product information does not list persistent cough among the most common adverse reactions. However, the adverse reactions section in official product information lists cough as an infrequent side effect that was observed in clinical research.

Q: Can Irbecor H be crushed, split, or chewed?

A: Official administration guidelines indicate that the tablet should be swallowed whole. There is no regulatory approval or instruction for crushing, splitting, or chewing the tablet. Because the tablet is a fixed-dose combination, official guidance advises against altering the form of the tablet to ensure correct delivery of both ingredients.

Q: Are there any known effects of Irbecor H on sexual function?

A: Official safety documents list certain forms of sexual dysfunction, such as decreased libido (decreased interest in sexual activity), among the possible infrequent or rare adverse reactions. These are classified as infrequent or rare adverse reactions in the official product information.

Q: Can Irbecor H be taken by people with gout?

A: The hydrochlorothiazide component (HCTZ) is a diuretic which may increase uric acid levels in the blood. Because of this action, official warnings document the concern that the medicine can potentially lead to new cases of gout or worsen existing gout symptoms.

Q: Is Irbecor H appropriate for older adults?

A: According to official regulatory documents, studies have not demonstrated age-related problems that would specifically limit the use of Irbecor H in the elderly. This indicates that there are no specific limitations for the use of the medicine based on age alone.

How should Irbecor H be stored and disposed of?

How to Store and Dispose of Irbecor H

The storage and disposal of Irbecor H, an oral tablet, must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

Temperature: Store at Controlled Room Temperature, generally defined as not exceeding 30°C.
Environment: The medicine must be kept in a cool, dry place, protected from excess heat, moisture, and direct light. Do not freeze the tablets.
Packaging: Keep the tablets in the original container or blister pack until the time of use, ensuring the container remains tightly closed.
Safety: The medication must be kept out of the sight and reach of children.

Disposal Instructions

Do not use the medicine past the expiration date on the package. Disposal of expired or unused Irbecor H must be managed through official channels. Do not throw away medicines via wastewater or household waste to protect the environment. Consult your pharmacist for specific instructions on local collection and disposal programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Georgia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z